Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001, 2: 127-137. 10.1038/35052073.
Article
CAS
PubMed
Google Scholar
Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol. 2003, 21: 2787-2799. 10.1200/JCO.2003.01.504.
Article
CAS
PubMed
Google Scholar
Lemmon MA: The EGF receptor family as therapeutic targets in breast cancer. Breast Dis. 2003, 18: 33-43.
Article
CAS
PubMed
Google Scholar
Hynes NE, Lane HA: ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005, 5: 341-354. 10.1038/nrc1609.
Article
CAS
PubMed
Google Scholar
Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C: HER2 expression in breast cancer primary tumours and corresponding metastases: original data and literature review. Br J Cancer. 2004, 90: 2344-2348.
CAS
PubMed
PubMed Central
Google Scholar
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235: 177-182. 10.1126/science.3798106.
Article
CAS
PubMed
Google Scholar
Sjögren S, Inganãs M, Lindgren A, Holmberg L, Bergh J: Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998, 16: 462-469.
PubMed
Google Scholar
Citri A, Skaria KB, Yarden Y: The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res. 2003, 284: 54-65. 10.1016/S0014-4827(02)00101-5.
Article
CAS
PubMed
Google Scholar
Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin BJ, Yarden Y: A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol. 1996, 16: 5276-5287.
Article
CAS
PubMed
PubMed Central
Google Scholar
Hendriks BS, Opresko LK, Wiley HS, Lauffenburger D: Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis. J Biol Chem. 2003, 278: 23343-23351. 10.1074/jbc.M300477200.
Article
CAS
PubMed
Google Scholar
Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. EMBO J. 1997, 16: 1647-1655. 10.1093/emboj/16.7.1647.
Article
CAS
PubMed
PubMed Central
Google Scholar
Baulida J, Kraus MH, Alimandi M, Di Fiore PP, Carpenter G: All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired. J Biol Chem. 1996, 271: 5251-5257. 10.1074/jbc.271.31.18989.
Article
CAS
PubMed
Google Scholar
Lenferink AE, Pinkas-Kramarski R, Poll van de ML, van Vugt MJ, Klapper LN, Tzahar E, Waterman H, Sela M, van Zoelen EJ, Yarden Y: Differential endocytic routing of homo- and hetero-dimeric ErbB tyrosine kinases confers signaling superiority to receptor heterodimers. EMBO J. 1998, 17: 3385-3397. 10.1093/emboj/17.12.3385.
Article
CAS
PubMed
PubMed Central
Google Scholar
Worthylake R, Opresko LK, Wiley HS: ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem. 1999, 274: 8865-8874. 10.1074/jbc.274.13.8865.
Article
CAS
PubMed
Google Scholar
Pinkas-Kramarski R, Shelly M, Glathe S, Ratzkin BJ, Yarden Y: Neu differentiation factor/neuregulin isoforms activate distinct receptor combinations. J Biol Chem. 1996, 271: 19029-19032. 10.1074/jbc.271.32.19029.
Article
CAS
PubMed
Google Scholar
Slamon D, Pegram M: Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001, 28: 13-19. 10.1016/S0093-7754(01)90188-5.
Article
CAS
PubMed
Google Scholar
Lin A, Rugo HS: The role of trastuzumab in early stage breast cancer: current data and treatment recommendations. Curr Treat Options Oncol. 2007, 8: 47-60. 10.1007/s11864-007-0008-2.
Article
PubMed
Google Scholar
Dean-Colomb W, Esteva FJ: Her2-positive breast cancer: herceptin and beyond. Eur J Cancer. 2008, 44: 2806-2812. 10.1016/j.ejca.2008.09.013.
Article
CAS
PubMed
Google Scholar
Fabi A, Metro G, Ferretti G, Giannarelli D, Di Cosimo S, Papaldo P, Mottolese M, Carlini P, Felici A, Russillo M, Cognetti F: Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A mono-institutional experience and systematic review of observational studies. Breast. 2008, 17: 499-505. 10.1016/j.breast.2008.03.006.
Article
PubMed
Google Scholar
Bayo-Calero JL, Mayordomo JI, Sánchez-Rovira P, Pérez-Carrión R, Illaramendi JJ, García-Bueno JM, González-Flores E, Crespo C, Ramos-Vázquez M, García-Palomo A, Ruiz-Borrego M, de la Haba J, Gómez-Bernal A, Yubero-Esteban A: A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. Clin Breast Cancer. 2008, 8: 264-268. 10.3816/CBC.2008.n.030.
Article
CAS
PubMed
Google Scholar
Perez EA, Baweja M: HER-2-positive breast cancer: current treatment strategies. Cancer Invest. 2008, 26: 545-552. 10.1080/07357900801971024.
Article
PubMed
Google Scholar
Storniolo AM, Pegram MD, Overmoyer B, Silverman P, Peacock NW, Jones SF, Loftiss J, Arya N, Koch KM, Paul E, Pandite L, Fleming RA, Lebowitz PF, Ho PT, Burris HA: Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2008, 26: 3317-3323. 10.1200/JCO.2007.13.5202.
Article
CAS
PubMed
Google Scholar
Schechter NR, Yang DJ, Azhdarinia A, Kohanim S, Wendt R, Oh CS, Hu M, Yu DF, Bryant J, Ang KK, Forster KM, Kim EE, Podoloff DA: Assessment of epidermal growth factor receptor with 99 mTc-ethylenedicysteine-C225 monoclonal antibody. Anticancer Drugs. 2003, 14: 49-56. 10.1097/00001813-200301000-00007.
Article
CAS
PubMed
Google Scholar
Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, Cocklin S, Williams JC, Papazoglou E, Rodeck U: Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther. 2008, 7: 726-733.
Article
CAS
PubMed
Google Scholar
Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L: A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 2004, 64: 6652-6659. 10.1158/0008-5472.CAN-04-1168.
Article
CAS
PubMed
Google Scholar
Widakowich C, De Castro G, De Azambuja E, Dinh P, Awada A: Review: side effects of approved molecular targeted therapies in solid cancers. The Oncologist. 2007, 12: 1443-1455. 10.1634/theoncologist.12-12-1443.
Article
CAS
PubMed
Google Scholar
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF, Hilsenbeck SG, Pavlick A, Zhang X, Chamness GC, Wong H, Rosen J, Chang JC: Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008, 100: 672-679. 10.1093/jnci/djn123.
Article
CAS
PubMed
Google Scholar
Huang Z, Brdlik C, Jin P, Shepard HM: A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther. 2009, 9: 97-110. 10.1517/14712590802630427.
Article
CAS
PubMed
Google Scholar
Raja SM, Clubb RJ, Bhattacharyya M, Dimri M, Cheng H, Pan W, Ortega-Cava C, Lakku-Reddi A, Naramura M, Band V, Band H: A combination of trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther. 2008, 7: 1630-1640. 10.1158/1535-7163.MCT-07-2409.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bache KG, Salgsvold T, Stenmark H: Defective downregulation of receptor tyrosine kinases in cancer. EMBO J. 2004, 23: 2707-2712. 10.1038/sj.emboj.7600292.
Article
CAS
PubMed
PubMed Central
Google Scholar
Park JW, Neve RM, Szollosi J, Benz CC: Unraveling the biologic and clinical complexities of HER2. Clin Breast Cancer. 2008, 8: 392-401. 10.3816/CBC.2008.n.047.
Article
CAS
PubMed
Google Scholar
Telli ML, Hunt SA, Carlson RW, Guardino AE: Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007, 25: 3525-3533. 10.1200/JCO.2007.11.0106.
Article
CAS
PubMed
Google Scholar
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007, 608: 1-22. full_text.
Article
CAS
PubMed
Google Scholar
Negendank WG: Studies of human tumors by MRS: a review. NMR Biomed. 1992, 5: 303-324.
Article
CAS
PubMed
Google Scholar
Podo F: Tumour phospholipid metabolism. NMR Biomed. 1999, 12: 413-439. 10.1002/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-U.
Article
CAS
PubMed
Google Scholar
Iorio E, Mezzanzanica D, Alberti P, Spadaro F, Ramoni C, D'Ascenzo S, Millimaggi D, Pavan A, Dolo V, Canevari S, Podo F: Alterations of choline phospholipid metabolism in ovarian tumor progression. Cancer Res. 2005, 65: 9369-9376. 10.1158/0008-5472.CAN-05-1146.
Article
CAS
PubMed
Google Scholar
Glunde K, Ackerstaff E, Mori N, Jacobs MA, Bhujwalla ZM: Choline phospholipid metabolism in cancer: consequences for molecular pharmaceutical interventions. Mol Pharm. 2006, 3: 496-506. 10.1021/mp060067e.
Article
CAS
PubMed
Google Scholar
Podo F, Sardanelli F, Iorio E, Canese R, Carpinelli G, Fausto A, Canevari S: Abnormal choline phospholipid metabolism in breast and ovary cancer: molecular bases for noninvasive imaging approaches. Curr Mol Imaging Rev. 2007, 3: 123-137. 10.2174/157340507780619160.
Article
CAS
Google Scholar
Ramoni C, Spadaro F, Barletta B, Dupuis ML, Podo F: Phosphatidylcholine-specific phospholipase C in mitogen-stimulated fibroblasts. Exp Cell Res. 2004, 299: 370-372. 10.1016/j.yexcr.2004.05.037.
Article
CAS
PubMed
Google Scholar
Cecchetti S, Spadaro F, Lugini L, Podo F, Ramoni C: Functional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cells. Eur J Immunol. 2007, 37: 2912-2922. 10.1002/eji.200737266.
Article
CAS
PubMed
Google Scholar
Spadaro F, Ramoni C, Mezzanzanica D, Miotti S, Alberti P, Cecchetti S, Iorio E, Dolo V, Canevari S, Podo F: Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells. Cancer Res. 2008, 68: 6541-6549. 10.1158/0008-5472.CAN-07-6763.
Article
CAS
PubMed
Google Scholar
Clark MA, Shorr RG, Bomalaski JS: Antibodies prepared to Bacillus cereus phospholipases C cross react with a phosphatidylcholine preferring phospholipases C in mammalian cells. Biochem Biophys Res Commun. 1986, 140: 114-119. 10.1016/0006-291X(86)91065-X.
Article
CAS
PubMed
Google Scholar
Podo F, Ferretti A, Knijn A, Zhang P, Ramoni C, Barletta B, Pini C, Baccarini S, Pulciani S: Detection of phosphatidylcholine-specific phospholipase C in NIH-3T3 fibroblasts and their H-ras transformants: NMR and immunochemical studies. Anticancer Res. 1996, 16: 1399-1412.
CAS
PubMed
Google Scholar
Ramoni C, Spadaro F, Menegon M, Podo F: Cellular localization and functional role of phosphatidylcholine-specific phospholipase C in NK cells. J Immunol. 2001, 167: 2642-2650.
Article
CAS
PubMed
Google Scholar
Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983, 65: 55-63. 10.1016/0022-1759(83)90303-4.
Article
CAS
PubMed
Google Scholar
Rubinstein LV, Shoemaker RH, Paull KD, Simm RM, Tosini S, Skehan P, Scadiero DA, Momks A, Boyd MR: Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst. 1990, 82: 1113-1120. 10.1093/jnci/82.13.1113.
Article
CAS
PubMed
Google Scholar
Spadaro F, Cecchetti S, Sanchez M, Ausiello CM, Podo F, Ramoni C: Expression and role of phosphatidylcholine-specific phospholipase C in human NK and T-lymphocyte subsets. Eur J Immunol. 2006, 36: 3277-3287. 10.1002/eji.200635927.
Article
CAS
PubMed
Google Scholar
Sargiacomo M, Sudol M, Tang Z, Lisanti MP: Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol. 1993, 122: 789-807. 10.1083/jcb.122.4.789.
Article
CAS
PubMed
Google Scholar
Zhu W, Okollie B, Artemov D: Controlled internalization of Her-2/neu receptors by cross-linking for targeted delivery. Cancer Biol Ther. 2007, 6: 1960-1966. 10.4161/cbt.6.12.4979.
Article
CAS
PubMed
Google Scholar
Hurwitz E, Stancovski I, Sela M, Yarden Y: Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake. Proc Natl Acad Sci USA. 1995, 92: 3353-3357. 10.1073/pnas.92.8.3353.
Article
CAS
PubMed
PubMed Central
Google Scholar
Longva KE, Pedersen NM, Haslekas C, Stang E, Madshus IH: Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int J Cancer. 2005, 116: 359-367. 10.1002/ijc.21015.
Article
CAS
PubMed
Google Scholar
Ginester C, Adélaïde J, Gonçalves A, Repellini L, Sircoulomb F, Letessier A, Finetti P, Geneix J, Charafe-Jauffret E, Bertuci F, Jacquemier J, Viens P, Birnbaum D: ERBB2 phosphorylation and trastuzumab sensitivity of breast cancer cell lines. Oncogene. 2007, 26: 7163-7169. 10.1038/sj.onc.1210528.
Article
Google Scholar
Cifone MG, Roncaioli P, De Maria R, Camarda G, Santoni A, Ruberti G, Testi R: Multiple pathways originate at the Fas/APO-1 (CD95) receptor: sequential involvement of phosphatidylcholine-specific phospholipase C and acidic sphingomyelinase in the propagation of the apoptotic signal. EMBO J. 1995, 14: 5859-5868.
CAS
PubMed
PubMed Central
Google Scholar
Liu X, Zhao Q, Araki S, Zhang S, Miao J: Contrasting effects of phosphatidylcholine-specific phospholipase C on apoptosis in cultured endothelial cells. Endothelium. 2006, 13: 205-211. 10.1080/10623320600760423.
Article
CAS
PubMed
Google Scholar
Zhao J, Zhao B, Wang W, Huang B, Zhang S, Miao J: Phosphatidylcholine-specific phospholipase C and ROS were involved in chicken blastodisc differentiation to vascular endothelial cell. J Cell Biochem. 2007, 102: 421-428. 10.1002/jcb.21301.
Article
CAS
PubMed
Google Scholar
Wang N, Xie K, Huo S, Zhao J, Zhang S, Miao J: Suppressing phosphatidylcholine-specific phospholipase C and elevating ROS level, NADPH oxidase activity and Rb level induced neuronal differentiation in mesenchymal stem cells. J Cell Biochem. 2007, 100: 1548-1557. 10.1002/jcb.21139.
Article
CAS
PubMed
Google Scholar
Glunde K, Jie C, Bhujwalla ZM: Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res. 2004, 64: 4270-4276. 10.1158/0008-5472.CAN-03-3829.
Article
CAS
PubMed
Google Scholar
Kappler LN, Waterman H, Sela M, Yarden Y: Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-cbl and enhancing ubiquitinylation of HER2. Cancer Res. 2000, 60: 3384-3388.
Google Scholar
Beerli RR, Wels W, Hynes NE: Intracellular expression of single-chain antibodies reverts ErbB-2 transformation. J Biol Chem. 1994, 269: 23931-23936.
CAS
PubMed
Google Scholar
Graus-Porta D, Beerli RR, Hynes NE: Single-chain antibody mediated intracellular retention of ErbB-2 impairs neu differentiation factor and epidermal growth factor signalling. Mol Cell Biol. 1995, 15: 1182-1191.
Article
CAS
PubMed
PubMed Central
Google Scholar
Le XF, Pruefer F, Bast RC: HER2-targeting antibodies modulate the cyclin-dependent kinase inhibitor p27Kip1 via multiple signaling pathways. Cell Cycle. 2005, 4: 87-95.
Article
CAS
PubMed
Google Scholar
Tamura K, Rice RL, Wipf P, Lazo JS: Dual G1 and G2/M phase inhibition by SC-ααδ9, a combinatorially derived Cdc25 phosphatase inhibitor. Oncogene. 1999, 18: 6989-6996. 10.1038/sj.onc.1203179.
Article
CAS
PubMed
Google Scholar
Vogt A, Pestell KE, Day BW, Lazo JS, Wipf P: The antisignaling agent SC-ααδ9,4-(benzy-(2-[(2,5-diphenyloxazole-4-carbonyl)amino]ethyl)carbamoyl-2-decanoylaminobutyric acid, is a structurally unique phospholipid analogue with phospholipase C inhibitory activity. Mol Cancer Ther. 2002, 1: 885-892.
CAS
PubMed
Google Scholar
Franklin CL, Li H, Martin SF: Design, synthesis, and evaluation of water-soluble phospholipid analogues as inhibitors of phospholipase C from Bacillus cereus. J Org Chem. 2003, 68: 7298-7307. 10.1021/jo034411k.
Article
CAS
PubMed
Google Scholar
Gonzalez-Roura A, Casas J, Llebaria A: Synthesis and phospholipase C inhibitory activity of D609 diastereomers. Lipids. 2002, 37: 401-406. 10.1007/s1145-002-0908-0.
Article
CAS
PubMed
Google Scholar
Müller-Decker K, Doppler C, Amtmann E, Sauer G: Interruption of growth signal transduction by an antiviral and antitumoral xanthate compound. Exp Cell Res. 1988, 177: 295-302. 10.1016/0014-4827(88)90463-6.
Article
PubMed
Google Scholar
Müller-Decker K: Interruption of TPA-induced signals by an antiviral and antitumoral xanthate compound: inhibition of a phospholipase C type reaction. Biochem Biophys Res Commun. 1989, 162: 198-205. 10.1016/0006-291X(89)91981-5.
Article
PubMed
Google Scholar
Amtmann E, Sauer G: Tumor necrosis factor induces necrosis of human carcinoma xenografts in the presence of tricyclodecan-9-yl-xanthogenate and lauric acid. Int J Cancer. 1990, 45: 1113-1118. 10.1002/ijc.2910450621.
Article
CAS
PubMed
Google Scholar
Sauer G, Amtmann E, Hofmann W: Systemic treatment of a human epidermoid non-small cell lung carcinoma xenograft with a xanthate compound causes extensive intratumoral necrosis. Cancer Letters. 1990, 53: 97-102. 10.1016/0304-3835(90)90200-H.
Article
CAS
PubMed
Google Scholar
Amtmann E: The antiviral, antitumoral xanthate D609 is a competitive inhibitor of phosphatidylcholine-specific phospholipase C. Drugs Exp Clin Res. 1996, 22: 287-294.
CAS
PubMed
Google Scholar